08.07.2020
VALBIOTIS: authorization to launch the international Phase II/III REVERSE-IT clinical study on TOTUM-63, to reduce Type 2 Diabetes risk factors
Download
12.06.2020
VALBIOTIS selected at the 80th Scientific Sessions of the American Diabetes Association to present Phase II clinical results of TOTUM-63 in prediabetes
Download
16.04.2020
VALBIOTIS accelerates the clinical development of its pipeline in new indications: reducing cardiovascular risk and hepatic steatosis
Download
02.04.2020
As part of a global partnership with Nestlé Health Science, VALBIOTIS initiates the pivotal late stage development phase of TOTUM-63, a plant-derived active substance with clinically demonstrated metabolic health benefits in people with prediabetes
Download
05.02.2020